Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis
dc.contributor.author | Kane, Sunanda V. | en_US |
dc.contributor.author | Cohen, Russell D. | en_US |
dc.contributor.author | Aikens, James E. | en_US |
dc.contributor.author | Hanauer, Stephen B. | en_US |
dc.date.accessioned | 2010-06-01T22:40:02Z | |
dc.date.available | 2010-06-01T22:40:02Z | |
dc.date.issued | 2001-10 | en_US |
dc.identifier.citation | Kane, Sunanda V.; Cohen, Russell D.; Aikens, James E.; Hanauer, Stephen B. (2001). "Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis." The American Journal of Gastroenterology 96(10): 2929-2933. <http://hdl.handle.net/2027.42/75640> | en_US |
dc.identifier.issn | 0002-9270 | en_US |
dc.identifier.issn | 1572-0241 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/75640 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11693328&dopt=citation | en_US |
dc.description.abstract | There are scant data regarding outpatient adherence in quiescent ulcerative colitis aside from patients enrolled in controlled clinical trials. We conducted a prevalence study to determine the medication adherence rate of maintenance therapy and to identify possible risk factors for nonadherence. METHODS : Outpatients with clinically quiescent ulcerative colitis for >6 months on maintenance mesalamine (Asacol, Procter and Gamble, Cincinnati, OH) were eligible. Patients were interviewed regarding disease history, and demographics were obtained from medical records. Refill information for at least 6 months was obtained from computerized pharmacy records. Adherence was defined as at least 80% consumption of supply dispensed. Using nonadherence as the outcome of interest, stratified analysis and regression modeling were used to identify significant associations. RESULTS : Data were complete for the 94 patients recruited. The overall adherence rate was found to be 40%. The median amount of medication dispensed per patient was 71% (8–130%) of the prescribed regimen. Nonadherent patients were more likely to be male (67% vs 52%, p < 0.05 ), single (68% vs 53%, p = 0.04 ), and to have disease limited to the left side of the colon versus pancolitis (83% vs 51%, p < 0.01 ). Sixty-eight percent of patients who took more than four prescription medications were found to be nonadherent versus only 40% of those patients taking fewer medications ( p = 0.05 ). Age, occupation, a family history of inflammatory bowel disease, length of remission, quality-of-life score, or method of recruitment (telephone interview vs clinical visit) were not associated with nonadherence. Logistic regression identified that a history of more than four prescriptions (odds ratio [OR] 2.5 [1.4–5.7]) and male gender (OR 2.06 [1.17–4.88]) increased the risk of nonadherence. Two statistically significant variables, which were protective against nonadherence, were endoscopy within the past 24 months (OR 0.96 [0.93–0.99]) and being married (OR 0.46 [0.39–0.57]). CONCLUSION : Nonadherence is associated with multiple concomitant medications, male gender, and single status. These patient characteristics may be helpful in targeting those patients at higher risk for nonadherence. | en_US |
dc.format.extent | 333348 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Inc | en_US |
dc.rights | 2001 by Am. Coll. of Gastroenterology | en_US |
dc.title | Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Family Medicine, University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | Department of Medicine, University of Chicago, Chicago, Illinois, USA | en_US |
dc.identifier.pmid | 11693328 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/75640/1/j.1572-0241.2001.04683.x.pdf | |
dc.identifier.doi | 10.1111/j.1572-0241.2001.04683.x | en_US |
dc.identifier.source | The American Journal of Gastroenterology | en_US |
dc.identifier.citedreference | Silverstein M., Lashner B., Hanauer S.. Cigarette smoking and ulcerative colitis: A case control study. Mayo Clinic Proc 1994; 69: 425 – 429. | en_US |
dc.identifier.citedreference | Fraga X., Vergara M., Medina C., et al. Effects of smoking on the presentation and clinical course of inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997; 9: 683. | en_US |
dc.identifier.citedreference | Evans J.M., McMahon A.D., Murray F.E., et al. Non-steroidal antiinflammatory drugs are associated with emergency hospital admission to hospital for colitis due to inflammatory bowel disease. Gut 1997; 40: 619 – 622. | en_US |
dc.identifier.citedreference | Felder J., Korelitz B., Rajapakse R., et al. Effect of nonsteroidal anti-inflammatory drugs on inflammatory bowel disease: A case-control study. Am J Gastroenterol 2000; 95: 1949 – 1954. | en_US |
dc.identifier.citedreference | Levenstein S., Prantera C., Varro V.. Stress and exacerbation in ulcerative colitis: A prospective study of patients enrolled in remission. Am J Gastroenterol 2000; 95: 1213 – 1220. | en_US |
dc.identifier.citedreference | 6. Mesalamine Study Group An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Ann Intern Med 1996; 124: 204 – 211. | en_US |
dc.identifier.citedreference | Ardizzone S., Petrillo M., Molteni P., et al. Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study. J Clin Gastroenterol 1995; 21: 287 – 289. | en_US |
dc.identifier.citedreference | Fockens P., Mulder C.J., Tytgat G.N., et al. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol 1995; 7: 1025 – 1030. | en_US |
dc.identifier.citedreference | Green J.R., Gibson J.A., Kerr G.D., et al. Maintenance of remission of ulcerative colitis: A comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator Group. Aliment Pharmacol Ther 1998; 12: 1207 – 1216. | en_US |
dc.identifier.citedreference | Miner P., Hanauer S., Robinson M., et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci 1995; 40: 296 – 304. | en_US |
dc.identifier.citedreference | Miller N.H.. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 102: 43 – 49. | en_US |
dc.identifier.citedreference | Truelove S.C., Witts L.J.. Cortisone in ulcerative colitis: Final report on a therapeutic trial. BMJ 1955; 2: 1041 – 1044. | en_US |
dc.identifier.citedreference | Irvine E.J., Zhou Q., Thompson A.K.. The Short Inflammatory Bowel Disease Questionnaire: A quality of life instrument for community physicians managing inflammatory bowel disease. Am J Gastroenterol 1996; 91: 1571 – 1578. | en_US |
dc.identifier.citedreference | Steiner J., Koepsell T.D., Fihn S.D., Inui T.S.. A general method of compliance assessment using centralized pharmacy records. Med Care 1988; 26: 814 – 823. | en_US |
dc.identifier.citedreference | Guyatt G.H., Sackett D.L., Cook D.J.. User's guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid ?. JAMA 1993; 270: 2598 – 2601. | en_US |
dc.identifier.citedreference | van Hees P.A., van Tongeren J.H.. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol 1982; 4: 333 – 336. | en_US |
dc.identifier.citedreference | Riley S., Mani V., Goddman M.J., Lucas S.. Why do patients with ulcerative colitis relapse ?. Gut 1990; 31: 179 – 183. | en_US |
dc.identifier.citedreference | Weidle P., Ganera C., Irwin K., et al. Adherence to antiretroviral medications in a minority population. J AIDS 1999; 22: 498 – 502. | en_US |
dc.identifier.citedreference | Willey C., Redding C., Stafford J.. Stages of change for adherence with medication regimens for chronic disease: Development and validation of a measure. Clin Ther 2000; 22: 858 – 871. | en_US |
dc.identifier.citedreference | Moody G.A., Jayanthi V., Probert C.S., et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: A retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 1179 – 1183. | en_US |
dc.identifier.citedreference | Eaden J., Abrams K., Ekbom A., et al. Colorectal cancer prevention in ulcerative colitis: A case-control study. Aliment Pharmacol Ther 2000; 14: 145 – 153. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.